| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Mayo Clinic Laboratories is a global leader in diagnostics dedicated to collaborative discoveries and patient breakthroughs. Together with Mayo Clinic, the authority in medicine, Mayo Clinic Laboratories relentlessly innovates on behalf of patients, building the diagnostics ecosystem of the future to help physicians save and improve more lives. We’re here to help you answer the toughest clinical questions, with access to the world’s most sophisticated test catalog and thousands of Mayo Clinic experts. With over 50 years of helping hospitals maximize the value of their labs, we have the expertise and knowledge to help you deliver care efficiently and effectively.
When physicians and their patients need answers, they rely on Mayo Clinic Laboratories.
“It is a great thing to make scientific discoveries of rare value, but it is even greater to be willing to share these discoveries and to encourage other workers in the same field of scientific research.”
William J. Mayo, M.D.
Putting the needs of patients first
The latest
After years of misdiagnosis, Tyler Hart found answers at Mayo Clinic, discovering he had NF155-IgG4 autoimmune nodopathy instead of CIDP
The quest to create a test pinpointing the source of the rare, testicular cancer-associated illness successfully concluded in the summer of 2021.
While Gregor Heinrich never could have imagined that testicular cancer was related to his problems with his vision and gait, learning he was positive for KLHL11 protein biomarkers meant he could receive treatment for both the cancer and the illness behind it.
As chair of Mayo Clinic’s new Division of Computational Pathology and AI in the Department of Laboratory Medicine and Pathology, Jason Hipp, M.D., Ph.D., is eager to employ the most innovative tools available to benefit patients around the globe.
Advanced testing at Mayo Clinic Laboratories that confirmed a diagnosis of myasthenia gravis put Lorinda McKinley on the road to renewed health after she nearly lost it all to the rare autoimmune disease.
In a newly published study, a team from Mayo Clinic’s Advanced Diagnostics Laboratory has developed a mass spectrometry-based assay that’s able to detect COVID-19 (SARS-CoV-2) pathogens from human proteins with, remarkably, 98% sensitivity and 100% specificity. This is the first assay of its kind that can detect viral antigens “directly from clinical specimens” such as nasopharyngeal swabs. Mass spectrometry is a sensitive technique used to detect, identify, and quantitate molecules present in a sample.
Dan O’Bryan didn’t think his dizziness and lightheadedness were anything to worry about. Nearly 100 miles away, the team at Mayo Clinic that was remotely monitoring Dan’s heart could see the truth.
Personalized medicine represents unprecedented potential benefits for patients. LabConnect and Mayo Clinic BioPharma Diagnostics are working together to bring world-class laboratory testing and resources to industry partners conducting clinical research and trials.
Before testing at Mayo Clinic Laboratories, Barbara Domaille, Deborah Neville, Pamela Neville, and Rylie Ronnenberg thought there could be a genetic connection to the hip problems they shared. After the testing, they knew for sure.
A web of innovation within Mayo Clinic Laboratories links research and test development with clinical practice, enabling for some of the world’s most pioneering methodologies. Underpinning this innovation network are unique supports that provide inventive and essential solutions to broaden testing capabilities.
It’s been understood for some time that an infection of B. mayonii, a rare species of bacterium, results in high levels of spirochetes in the peripheral blood. But actually being able to visualize them on a routine peripheral blood smear may allow for improved recognition of this uncommon cause of Lyme disease.
Mayo Clinic renal pathologist Dr. Sanjeev Sethi identified NELL-1 as a biomarker for membranous nephropathy (MN) in 2019. Two years later, Dr. Sethi helped implement the first ever IHC test to detect NELL-1 antigen, which appears in about 10% of MN patients and is linked to underlying malignancy.
Delta Health leveraged their relationship with Mayo Clinic Laboratories to support patient in rural Colorado during the COVID-19 pandemic. Delta Health and Mayo Clinic Laboratories have collaborated for over 17 years to perform complex and esoteric testing.